This paper included 5 studies that randomized patients to conventional stent versus chromium cobalt everolimus eluting stent; at 2 years, a significantly lower risk of cardiac death (2.7% for the everolimus eluting stent versus 4% for conventional stent, p = 0013) was observed. Myocardial infarction was reduced by over 80% with drug-eluting stent (0.08% versus 0.8%, P = 0.003). Regarding definite thrombosis differences favoring the drug eluting stent with 0.6% versus 1.4% (p = 0.005) were also observed.
Conclusion
The analysis of 5 randomized studies with a total of 4896 patients showed a consistent reduction in fatal and nonfatal ischemic events.
Marco Valgimigli
2014-05-22
Title: Effects of cobalt-chromium everolimus-eluting or bare-metal stent on fatal and non-fatal cardiovascular events: a collaborative patient-level meta-analysis, including 4,896 individuals with a median 2-year follow-up duration
